Abstract
The 'omics' technologies represent analytical approaches that have a holistic view on molecules such as genes, transcripts, proteins and metabolites constituting a cell, tissue or organism. The profiling of genes, transcripts and proteins has been referred to as genomics, transcriptomics and proteomics. Finally, there is the youngest and most rapidly increasing of the “omics” disciplines: metabolomics. Metabolomics appears to be a new, very useful tool in neonatology, especially in the fields of pharma-metabolomics and nutri- metabolomics. Since it appears to be predictive and preventive, it can be considered the ‘new clinical chemistry’ for personalized neonatal medicine. At present, the use of metabolomics in neonatology is still in the pioneering phase. In clinical practice, only a limited number of metabolites are routinely measured in the biofluids of newborns by conventional analytical methods to study the metabolic status of the organism. However, the management of sick or preterm newborns might be improved if more information on perinatal/ neonatal maturational processes and their metabolic background were available.
The aim of this review, after a general introduction on pharma-metabolomics, is to present the potential of NMR-based metabolomic analysis of newbom urine in neonatology in the field of pharmacology.
Keywords: Metabolomics, newborn, drugs, therapy, genes, transcripts, proteins, neonatology, biofluids, pharmacology
Current Pharmaceutical Design
Title:Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Volume: 18 Issue: 21
Author(s): Vassilios Fanos, Luigi Barberini, Roberto Antonucci and Luigi Atzori
Affiliation:
Keywords: Metabolomics, newborn, drugs, therapy, genes, transcripts, proteins, neonatology, biofluids, pharmacology
Abstract: The 'omics' technologies represent analytical approaches that have a holistic view on molecules such as genes, transcripts, proteins and metabolites constituting a cell, tissue or organism. The profiling of genes, transcripts and proteins has been referred to as genomics, transcriptomics and proteomics. Finally, there is the youngest and most rapidly increasing of the “omics” disciplines: metabolomics. Metabolomics appears to be a new, very useful tool in neonatology, especially in the fields of pharma-metabolomics and nutri- metabolomics. Since it appears to be predictive and preventive, it can be considered the ‘new clinical chemistry’ for personalized neonatal medicine. At present, the use of metabolomics in neonatology is still in the pioneering phase. In clinical practice, only a limited number of metabolites are routinely measured in the biofluids of newborns by conventional analytical methods to study the metabolic status of the organism. However, the management of sick or preterm newborns might be improved if more information on perinatal/ neonatal maturational processes and their metabolic background were available.
The aim of this review, after a general introduction on pharma-metabolomics, is to present the potential of NMR-based metabolomic analysis of newbom urine in neonatology in the field of pharmacology.
Export Options
About this article
Cite this article as:
Fanos Vassilios, Barberini Luigi, Antonucci Roberto and Atzori Luigi, Pharma-metabolomics in Neonatology: is it a Dream or a Fact?, Current Pharmaceutical Design 2012; 18 (21) . https://dx.doi.org/10.2174/1381612811209022996
DOI https://dx.doi.org/10.2174/1381612811209022996 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial from Guest Editor [Hot Topic:Vitamin D and Respiratory Health (Guest Editor: Adrian R. Martineau)]
Current Respiratory Medicine Reviews Exploring Polypharmacology in Drug Discovery and Repurposing Using the CANDO Platform
Current Pharmaceutical Design The Structure-Function Relationships of Complement Receptor Type 2 (CR2; CD21)
Current Protein & Peptide Science Double-Faced Role of Human Mesenchymal Stem Cells and their Role/Challenges in Cancer Therapy
Current Stem Cell Research & Therapy L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine The Shape of the Messenger: Using Protein Structure Information to Design Novel Cytokine-based Therapeutics
Current Pharmaceutical Design Non-Invasive Cell Tracking in Cancer and Cancer Therapy
Current Topics in Medicinal Chemistry Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
Current Cancer Therapy Reviews Receptor Tyrosine Kinases Take a Direct Route to Mitochondria: An Overview
Current Protein & Peptide Science Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Organophosphorus Chemistry: Therapeutic Intervention in Mechanisms of Viral and Cellular Replication
Current Organic Chemistry Targeting ABCB1 and ABCC1 with their Specific Inhibitor CBT-1<sup>®</sup> can Overcome Drug Resistance in Osteosarcoma
Current Cancer Drug Targets Patents in Cancer Stem Cells
Recent Patents on Biomarkers Editorial Review of 2012
Current Radiopharmaceuticals Advances in the Molecular Detection of ABC Transporters Involved in Multidrug Resistance in Cancer
Current Pharmaceutical Biotechnology COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Mini-Reviews in Medicinal Chemistry Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies
Current Pharmaceutical Design Biomolecules of Human Female Fertility - Potential Therapeutic Targets for Pharmaceutical Design
Current Pharmaceutical Design Utility of Assessing Thiopurine S-methyltransferase Polymorphisms Before Azathioprine Therapy
Current Drug Metabolism Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis
Current Pharmaceutical Design